Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tunable 3.75-4.35  µm optical parametric generation using cascaded non-critical phase matching in CdSiP<sub>2</sub>.

Applied optics·2026
Same author

Generating fair, reliable, and accurate neuropsychological test norms for people with HIV in a low- or middle-income country.

Journal of neurovirology·2024
Same author

Trends in lung cancer diagnosis and care among visible minorities and non-visible minorities in Canada.

Cancer causes & control : CCC·2023
Same author

Dissociable roles of thalamic nuclei in the refinement of reaches to spatial targets.

bioRxiv : the preprint server for biology·2023
Same author

Big data from small animals: integrating multi-level environmental data into the Dog Aging Project.

Revue scientifique et technique (International Office of Epizootics)·2023
Same author

Exploration biases how forelimb reaches to a spatial target are learned.

bioRxiv : the preprint server for biology·2023

Related Experiment Video

Updated: Jun 13, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

A screening algorithm for HIV-associated neurocognitive disorders.

L A Cysique1, J M Murray, M Dunbar

  • 1Brain Sciences, University of New South Wales, Sydney, Australia.

HIV Medicine
|May 12, 2010
PubMed
Summary
This summary is machine-generated.

A new, brief algorithm accurately predicts HIV-associated neurocognitive impairment (HAND) in HIV-positive patients. This tool helps identify individuals needing further neurological assessment, improving management for those with advanced HIV disease.

More Related Videos

High Content Screening in Neurodegenerative Diseases
13:32

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Related Experiment Videos

Last Updated: Jun 13, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

High Content Screening in Neurodegenerative Diseases
13:32

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Area of Science:

  • Neuroscience
  • Infectious Diseases
  • Clinical Medicine

Background:

  • HIV physicians face time constraints for cognitive screening.
  • HIV-associated neurocognitive impairment (HAND) requires timely identification.
  • A need exists for a rapid, clinically applicable screening tool for HAND.

Purpose of the Study:

  • To develop and validate a brief, non-cognitive screening tool for predicting HAND in HIV-positive individuals.
  • To identify patients with advanced HIV disease who require comprehensive neurological/neuropsychological assessment.

Main Methods:

  • Developed a screening algorithm using support vector machines.
  • Classified 97 HIV-positive individuals with advanced disease into NP-impaired and NP-normal groups.
  • Utilized predictors including age, CD4 count, CNS HIV history, and treatment duration.

Main Results:

  • The final algorithm achieved 78% overall prediction accuracy and 70% specificity.
  • The screening tool requires approximately 3 minutes to complete.
  • Key predictors included age, current CD4 cell count, past CNS HIV diseases, and treatment duration.

Conclusions:

  • The non-cognitive algorithm is effective for identifying HIV patients at high risk of HAND.
  • Proposed staged guidelines for improved HAND therapeutic management.
  • Recommended initial use for HIV-infected Caucasian men with advanced disease, with future studies planned.